Immunotherapy for pemphigus and bullous pemphigoid

Area of Science:

• Immunology
• Dermatology
• Autoimmune Diseases

Background:

• Pemphigus and bullous pemphigoid (BP) are distinct autoimmune bullous diseases (AIBD).
• Pemphigus involves intraepidermal blisters (anti-desmosome antibodies), while BP features subepidermal blisters (anti-epidermal-dermal junction antibodies).
• Conventional treatments rely on systemic glucocorticoids and immunosuppressants.

Purpose of the Study:

• To review recent advancements in immunotherapy for pemphigus and BP.
• To discuss the clinical applications of novel immune-targeted therapies.
• To highlight the evolving treatment landscape for these major AIBDs.

Main Methods:

• Literature review of recent clinical studies and trials.
• Analysis of immunotherapy mechanisms and efficacy.
• Synthesis of data on novel biologic agents and targeted therapies.

Main Results:

• Rituximab (anti-CD20) is effective as a first-line treatment for pemphigus.
• Dupilumab (anti-IL-4 receptor) shows promise for refractory BP, linked to Type 2 inflammation.
• Various immune-targeted therapies are under investigation for both conditions.

Conclusions:

• Immunotherapy represents a significant advancement in managing pemphigus and BP.
• Targeted biologic agents offer new hope for patients with refractory disease.
• Continued research into immune-targeted therapies is crucial for optimizing AIBD treatment.